Abstract
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways
Scientific Reports Open Access 13 July 2020
-
Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level
Scientific Reports Open Access 15 October 2018
-
A pH-induced conformational switch in a tyrosine kinase inhibitor identified by electronic spectroscopy and quantum chemical calculations
Scientific Reports Open Access 24 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).
Cersosimo, R. J. Lung cancer: a review. Am. J. Health Syst. Pharm. 59, 611–642 (2002).
Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for the treatment of cancer. Nature Rev. Drug Discov. 2, 296–313 (2003).
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).
Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 7 (S4), 2–8 (2002).
Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995).
Moyer, J. D. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838–4848 (1997).
Pollack, V. A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291, 739–748 (1999).
FDA label information [online], <http://www.fda.gov/cder/foi/label/2004/021743lbl.pdf> (2004).
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl J. Med. 350, 2129–2139 (2004).
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Shigematsu, H. et al. Clinical and biological features of epidermal growth factor receptor mutations in lung cancers. J. Natl Cancer Inst. (in the press).
Sandler Sandler, A. et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. 22, 14S (2004).
Pao Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci USA 101, 13306–13311 (2004).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Dowell, J., Minna, J. & Kirkpatrick, P. Erlotinib hydrochloride. Nat Rev Drug Discov 4, 13–14 (2005). https://doi.org/10.1038/nrd1612
Issue Date:
DOI: https://doi.org/10.1038/nrd1612
This article is cited by
-
Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents
Molecular Diversity (2023)
-
Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways
Scientific Reports (2020)
-
Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level
Scientific Reports (2018)
-
A pH-induced conformational switch in a tyrosine kinase inhibitor identified by electronic spectroscopy and quantum chemical calculations
Scientific Reports (2017)
-
Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging
Scientific Reports (2017)